» Articles » PMID: 17546836

Early Changes in Ghrelin Following Roux-en-Y Gastric Bypass: Influence of Vagal Nerve Functionality?

Overview
Journal Obes Surg
Date 2007 Jun 6
PMID 17546836
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Roux-en-Y gastric bypass (RYGBP) effectively produces massive weight reduction, improving health in morbidly obese patients. The mechanisms for the weight loss, and the fate of the excluded gastric mucosa, are not fully clarified. To what extent the appetite-stimulating gastric peptide ghrelin is affected remains controversial.

Methods: Circulating concentrations of ghrelin, pancreatic polypeptide (PP), pepsinogen I (PGI) and gastrin were examined in 15 morbidly obese patients (median BMI 45 kg/m2) preoperatively, and on days 1, 2, 4, 6 and at months 1, 6 and 12 after RYGBP.

Results: Ghrelin levels fell on postoperative day 1 and increased after 1 month to preoperative levels, and rose further at 6 and 12 months. PP concentrations decreased on day 1 and subsequently returned to preoperative levels. PGI levels peaked transiently the first days after surgery and subsequently declined to lower than preoperative levels. Gastrin levels were gradually reduced postoperatively.

Conclusion: Ghrelin and PP fall transiently after surgery, possibly due to vagal dysfunction, and ultimately, as weight loss ensues, ghrelin secretion increases to higher than preoperative levels. The RYBGP procedure affects the gastric mucosa, as reflected by a transient increase in circulating PGI, and subsequently, the mucosa in the excluded stomach is at rest, as shown by low levels of PGI and gastrin.

Citing Articles

Endocrine Dysfunction Following Bariatric Surgery: A Systematic Review of Postoperative Changes in Major Endocrine Hormones.

Shahid Tanweer A, Shaheen M, Alshamsi B, Almazrouei M, Almasri R, Shahid Tanveer A Cureus. 2025; 17(1):e77756.

PMID: 39981480 PMC: 11842000. DOI: 10.7759/cureus.77756.


Mechanisms of bariatric surgery for weight loss and diabetes remission.

Yin M, Wang Y, Han M, Liang R, Li S, Wang G J Diabetes. 2023; 15(9):736-752.

PMID: 37442561 PMC: 10509523. DOI: 10.1111/1753-0407.13443.


The role of the gastric fundus in glycemic control.

Kehagias D, Georgopoulos N, Habeos I, Lampropoulos C, Mulita F, Kehagias I Hormones (Athens). 2023; 22(2):151-163.

PMID: 36705877 DOI: 10.1007/s42000-023-00429-7.


Neurohormonal Changes in the Gut-Brain Axis and Underlying Neuroendocrine Mechanisms following Bariatric Surgery.

Martinou E, Stefanova I, Iosif E, Angelidi A Int J Mol Sci. 2022; 23(6).

PMID: 35328759 PMC: 8954280. DOI: 10.3390/ijms23063339.


Gastrointestinal peptides in eating-related disorders.

Smith K, Moran T Physiol Behav. 2021; 238:113456.

PMID: 33989649 PMC: 8462672. DOI: 10.1016/j.physbeh.2021.113456.


References
1.
Katsuura G, Asakawa A, Inui A . Roles of pancreatic polypeptide in regulation of food intake. Peptides. 2002; 23(2):323-9. DOI: 10.1016/s0196-9781(01)00604-0. View

2.
Maier C, Schaller G, Buranyi B, Nowotny P, Geyer G, Wolzt M . The cholinergic system controls ghrelin release and ghrelin-induced growth hormone release in humans. J Clin Endocrinol Metab. 2004; 89(9):4729-33. DOI: 10.1210/jc.2004-0656. View

3.
Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y . Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol. 1998; 93(7):1090-6. DOI: 10.1111/j.1572-0241.1998.00335.x. View

4.
Kodoi A, Yoshihara M, Sumii K, Haruma K, Kajiyama G . Serum pepsinogen in screening for gastric cancer. J Gastroenterol. 1995; 30(4):452-60. DOI: 10.1007/BF02347560. View

5.
Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H . The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology. 2002; 123(4):1120-8. DOI: 10.1053/gast.2002.35954. View